The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Gennady Bratslavsky
Employment - AptaMatrix
Leadership - Taurus Diagnostics
Stock and Other Ownership Interests - Ilgen; Respiquest
Consulting or Advisory Role - Johnson & Johnson/Janssen; Novartis
 
Joseph M Jacob
Consulting or Advisory Role - Photocure; Verity Pharmaceuticals
Speakers' Bureau - Urogen pharma
 
Oleksandr Kravtsov
No Relationships to Disclose
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
David R Wise
Honoraria - OncLive
Consulting or Advisory Role - Alphasights; Foundation Medicine; Gerson Lehrman Group; Guidepoint Global; Janssen; LabCorp; Leap Therapeutics; Myovant Sciences; Pfizer; silverlight
Travel, Accommodations, Expenses - Pfizer
 
Natalie Danziger
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Vamsi Parimi
Employment - Foundation Medicine
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Submitted patent for HRD calling methodology (Inst)
 
Hanna Tukachinsky
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Mia Alyce Levy
Employment - Foundation Medicine; SeqTech Diagnostics (I)
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Royalties from GenomOncology for licensing of MyCancerGenome content
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine